Document Classification

Section Type: METHODS

Text: Patients with advanced metastatic melanoma were randomly assigned to receive dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 on days 1 to 3 combined with interferon-alfa-2b 10 x 10 (6) U/m2 subcutaneously on days 1 through 5 without (arm A) or with (arm B) a high-dose intravenous decrescendo regimen of IL-2 on days 5 through 10 (18 x 10 (6) U/m2/6 hours, 18 x 10 (6) U/m2/12 hours, 18 x 10 (6) U/m2/24 hours, and 4. 5 x 10 (6) U/m2 for 3 x 24 hours).